

Idaho DUR Committee Meeting Record

Date: July 21, 2011 **Time:** 9:00 a.m. – 3:00 p.m. **Location:** Idaho Medicaid, 3232 Elder Street, Conference Room D-West

Moderator: Mark Turner, MD

Committee Members Present: Perry Brown, MD, Paul Cady, Pharm.D., Wayne Baures, RPh, Janet Mayo, Pharm.D., Suzette Cooper, Pharm.D., Myrna Olson-Fisher, NP, and Mark Turner, M.D.

Others Present: Jane Gennrich, Pharm.D., Mark England, Pharm.D., and William Milne, RPh

Committee Members Absent: Erich Garland, MD

AGENDA ITEMS	PRESENTER	OUTCOME/ACTIONS
Committee Business		
➤ <i>Call to order</i>	Mark Turner, MD	
➤ <i>Approval of Minutes from April 14, 2011</i>	Mark Turner, MD	Minutes approved.
➤ <i>General Discussion</i>	Perry Brown, MD	Proposed an email option for receiving DUR Board information on an Opt-in or Opt-out basis Collaborative group forming 10/1/2011 regarding pediatric asthma & improving treatment. Leukotriene use versus inhaled corticosteroids is a topic for the collaborative group.
➤ <i>Follow-up Studies – updates</i>	Mark England, Pharm.D.	As of 7/5/2011 - 42 responses have been received (24% response rate). As of 7/5/2011 – 16 responses have been received (25% response rate). As of 7/5/2011 – 113 responses have been received (24% response rate). – Discussed exploring other therapeutic options such as H2 blockers. Include PPI information in the newsletter.
○ <i>Tramadol with SSRIs or SNRIs</i>		
○ <i>Thiazolidinedione safety</i>		
○ <i>Proton Pump Inhibitors – Long Term continuous use</i>		

<p>➤ <i>Current Interventions/Outcome studies</i></p> <ul style="list-style-type: none"> ○ Colchicine Usage – place in therapy for treatment of gout ○ Ketorolac DUR ○ Tramadol with SSRIs or SNRIs – potential for Serotonin Syndrome – pharmacy provider profiling. 	<p>Jane Gennrich, Pharm.D.</p> <p>Mark England, Pharm.D.</p> <p>Mark England, Pharm.D.</p>	<p>Discussed the June 2006 FDA drug safety initiative to remove unapproved drugs from the market which included colchicine. Colcris was introduced in July 2009 and approved for Acute flares on 7/29/09 and for Chronic Gout on 10/16/09. (See Meeting slides for complete presentation – available on IDHW website). 23 patient profiles were evaluated (Meeting slides contain complete evaluation results)</p> <p>It was discovered while reviewing drug database updates that the maximum quantity for Ketorolac had been set at 10 tablets per day, which was immediately changed to 4 tablets per day which is the maximum FDA approved dose. Report generated to review patients on high doses and retroDUR review was deemed appropriate. The multiple risks involved with high dose and long duration Ketorolac were reviewed. 29 patient profiles were evaluated and letters were sent to 9 prescribers regarding 9 patients on 6/20/2011.</p> <p>As of 7/7/2011, 3 responses have been received (33% response rate).</p> <p>Profiles are being generated and are currently in the process of being sent out along with the Serotonin Syndrome handout</p>
<p>➤ Working Lunch</p>	<p>12:00 – 1:00</p> <p>Perry Brown, MD</p>	<p>Further discussion of the morning topics</p> <p>Dr. Brown discussed Nexium being switched to non-preferred status and the negative effect on the provider network. Notification requirements were reviewed plus the savings that will result from the change.</p>
<p>➤ Afternoon Session</p>		
<p>➤ <i>Study Proposals for Next Quarter</i></p> <ul style="list-style-type: none"> ○ <i>Analysis of Auto Refill Practices (update current status)</i> 	<p>Mark England, Pharm.D.</p>	<p>Some pharmacy providers are instituting Auto Refill policies which allow them to automatically dispense refills based on days since last fill. (Survey results were included in the DUR Board packet)</p>
<ul style="list-style-type: none"> ○ <i>Atypical Antipsychotic: Impact of P&T Recommendations.</i> 	<p>Jane Gennrich, Pharm.D.</p>	<p>The Atypical Antipsychotic recommendations from the P&T committee have not been able to be implemented yet due to technical issues with the pharmacy program being unable to electronically receive ICD-9 diagnosis codes.</p>

<ul style="list-style-type: none"> ○ High Dose utilization through multiple strengths of selected medications <ul style="list-style-type: none"> ● Focalin XR ● Atypical antipsychotics 	<p>Mark England, Pharm.D.</p>	<p>4 recipients received multiple strengths of Focalin XR over 2Q2011.</p> <p>417 recipients received multiple doses of the same atypical antipsychotic over 2Q2011.</p>
<ul style="list-style-type: none"> ○ Injectable Atypical antipsychotics. 	<p>Mark England, Pharm.D.</p>	<p>Evaluate adherence rates and program integrity. The study responsibilities were outlined for the Medicaid Staff, MMA, DUR Board and P&T Committee.</p>
<ul style="list-style-type: none"> ○ Narcotic Analgesic Studies – from P&T Committee 	<p>Mark England, Pharm.D.</p>	<p>The discussion of the many options and size potential for this combination of studies created many ideas and some concerns to consider. The committee referred it back to the Pharmacy Unit and Magellan staff for further review.</p>
<ul style="list-style-type: none"> ○ Re-run Synagis study for 2010 – 2011 season. 	<p>Jane Gennrich, Pharm.D.</p>	<p>The same criteria used to review the 2009-2010 RSV season will be used to review the 2010-2011 season.</p>
<ul style="list-style-type: none"> ○ Hep C Treatment 	<p>Jane Gennrich, Pharm.D.</p>	<p>Two new and very expensive drugs to treat hepatitis C have recently been approved by the FDA. In addition, cost differences between the commercially available forms of ribavirin were reviewed.</p>
<ul style="list-style-type: none"> ➤ <i>ProDUR Quarterly Report</i> 	<p>Mark England, Pharm.D.</p>	<p>Reviewed Quarterly Report – the focus review edit for this quarter was Early Refill by DUR</p>
<ul style="list-style-type: none"> ➤ <i>DUR Quarterly Newsletter</i> 	<p>Ideas from the Board</p>	<p>Suggested topics included: New Preferred Agents. Enrolling for Email delivery, Multiple prescriber issues – an explanation of lettering practices, PPI usage regarding reduced magnesium levels leading to osteoporosis, the DUR Mission (content and objectives), Explain the new response forms.</p>

<p>➤ Medicaid Update</p> <p>➤ <i>Adjourn, 3:00 p.m.</i></p>	<p>Jane Gennrich, Pharm.D</p>	<p>Dr. Gennrich reported on some progress in medical claim information now being sent to the pharmacies for Point of Sale claims processing but there are ongoing issues with RetroDUR regarding medical claims.</p> <p>The Next DUR Board Meeting will be held October 20, 2011 - 9am-4pm at 3232 Elder Street.</p>
---	-------------------------------	--